
In July 2012, Congress passed the Food and Drug Administration Safety and Innovation Act zzso The zzso zzso zzso for Patients Act was incorporated into a Title of zzso to zzso clinical development of new, potential zzso drugs or treatments that show dramatic responses in zzso zzso Using this regulatory pathway, once a promising new drug candidate is designated as a zzso zzso the zzso Food and Drug Administration zzso and sponsor would collaborate to determine the best path forward to zzso the traditional zzso approach to drug zzso The breakthrough legislation requires that an zzso guidance be drafted that details specific requirements of the bill to aid zzso in implementing requirements of the zzso In this article, we have proposed criteria to define a product as a zzso zzso and discussed critical components of the development process that would require flexibility in order to enable expedited development of a zzso zzso 

